当前位置: 首页 >> 检索结果
4601. Interaction between exercise training and ejection fraction in predicting prognosis after a first myocardial infarction.
作者: G Specchia.;S De Servi.;A Scirè.;J Assandri.;C Berzuini.;L Angoli.;M T La Rovere.;F Cobelli.
来源: Circulation. 1996年94卷5期978-82页
Although recent meta-analysis trials have shown that exercise training may improve survival after myocardial infarction, the mechanism of this beneficial effect is still unknown. The purpose of this study was to detect possible interactions between exercise training and predictors of prognosis after a first myocardial infarction.
4602. Mortality after 16 years for participants randomized to the Multiple Risk Factor Intervention Trial.
来源: Circulation. 1996年94卷5期946-51页
A mortality follow-up of 12,866 men was conducted 16 years after randomization to special intervention (SI) or usual care (UC) groups of the Multiple Risk Factor Intervention Trial to assess the long-term effect of cardiovascular risk factor intervention on coronary heart disease (CHD), cardiovascular death (CVD), and total mortality.
4603. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial.
The TIMI 9 trial evaluated whether the direct antithrombin hirudin is more effective than an indirect-acting antithrombin, heparin, as adjunctive therapy for thrombolysis in myocardial infarction.
4604. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention.
作者: D J Kereiakes.;J P Runyon.;N S Kleiman.;N A Higby.;L C Anderson.;G Hantsbarger.;S McDonald.;R J Anders.
来源: Circulation. 1996年94卷5期906-10页
Placebo-controlled randomized trials of parenteral platelet glycoprotein (GP) IIb/IIIa receptor antagonists have demonstrated reduced ischemic complications of coronary angioplasty. Orally active GP IIb/IIIa blockers are being developed to allow more sustained receptor antagonism with potential for long-term secondary prevention. Sequential therapy with abciximab followed by an oral IIb/IIIa antagonist has not previously been reported. The clinical safety and pharmacodynamics of a sequential therapeutic strategy are unknown.
4605. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study.
作者: P Théroux.;S Kouz.;L Roy.;M L Knudtson.;J G Diodati.;J F Marquis.;J Nasmith.;A Y Fung.;J R Boudreault.;F Delage.;R Dupuis.;C Kells.;M Bokslag.;B Steiner.;H J Rapold.
来源: Circulation. 1996年94卷5期899-905页
Ligand binding to the platelet membrane receptor glycoprotein (GP) IIb/IIIa, the final and obligatory step to platelet aggregation, can now be inhibited by pharmacological agents. This study was designed to evaluate the potential of lamifiban, a novel nonpeptide antagonist of GP IIb/IIIa, for the management of unstable angina.
4606. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
作者: C Bode.;R W Smalling.;G Berg.;C Burnett.;G Lorch.;J M Kalbfleisch.;R Chernoff.;L G Christie.;R L Feldman.;A A Seals.;W D Weaver.
来源: Circulation. 1996年94卷5期891-8页
The therapeutic benefit of thrombolytic therapy has been shown to correlate directly with completeness (TIMI grade 3 flow) and speed of reperfusion of the infarct-related coronary artery. The purpose of the RAPID II study was to determine whether a double-bolus regimen of reteplase, a recently developed deletion mutant of wild-type tissue plasminogen activator, could improve 90-minute coronary artery patency rates achieved with the most successful standard regimen, an "accelerated" front-loaded infusion of alteplase.
4607. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.
作者: C R Benedict.;B Shelton.;D E Johnstone.;G Francis.;B Greenberg.;M Konstam.;J L Probstfield.;S Yusuf.
来源: Circulation. 1996年94卷4期690-7页
Elevated plasma neurohormonal levels are associated with increased mortality rates in patients with symptomatic heart failure. A previous Studies of Left Ventricular Dysfunction (SOLVD) trial suggested that neurohumoral activation precedes the development of symptoms as demonstrated by increased neurohormonal levels in patients with asymptomatic left ventricular dysfunction. However, the significance of this early neurohumoral activation is unclear. The goals of this study were to determine the prognostic significance of the plasma concentrations of plasma norepinephrine (PNE) and atrial natriuretic peptide (ANP) and the renin activity (PRA) in patients with asymptomatic left ventricular dysfunction.
4608. Changes in early and late diastolic filling patterns induced by long-term adrenergic beta-blockade in patients with idiopathic dilated cardiomyopathy.
作者: B Andersson.;K Caidahl.;A di Lenarda.;S E Warren.;F Goss.;A Waldenström.;S Persson.;I Wallentin.;A Hjalmarson.;F Waagstein.
来源: Circulation. 1996年94卷4期673-82页
beta-Blockers have been used in patients with idiopathic dilated cardiomyopathy to improve cardiac performance and theoretically would be beneficial to diastolic function. However, there are few reports on changes in diastolic function during chronic pharmacological treatment of congestive heart failure.
4609. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators.
作者: D B Mark.;J D Talley.;E J Topol.;L Bowman.;L C Lam.;K M Anderson.;J G Jollis.;M W Cleman.;K L Lee.;T Aversano.;W J Untereker.;L Davidson-Ray.;R M Califf.
来源: Circulation. 1996年94卷4期629-35页
In the EPIC trial, c7E3 Fab, an antiplatelet IIb/ IIIa receptor antibody, reduced 30-day ischemic end points after high-risk coronary angioplasty by 35% and 6-month ischemic events by 23% but increased in-hospital bleeding episodes.
4610. Effects of cigarette smoking on the angiographic evolution of coronary atherosclerosis. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) Substudy. CCAIT Study Group.
作者: D Waters.;J Lespérance.;P Gladstone.;S J Boccuzzi.;T Cook.;R Hudgin.;G Krip.;L Higginson.
来源: Circulation. 1996年94卷4期614-21页
Although smoking increases both the risk of developing coronary disease and the risk of coronary events in patients with known coronary atherosclerosis, the effect of smoking on the evolution of coronary atherosclerosis as assessed by serial angiography is poorly defined.
4611. Acute hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hypertension.
作者: D J Williamson.;C Hayward.;P Rogers.;L L Wallman.;A D Sturgess.;R Penny.;P S Macdonald.
来源: Circulation. 1996年94卷3期477-82页
Inhaled nitric oxide (NO) is a selective pulmonary vasodilator that reduces pulmonary vascular resistance (PVR) in patients with primary pulmonary hypertension. Their responses to inhaled NO predict their responses to other vasodilators, such as prostacyclin, and provide an estimate of the "fixed" component of their increased PVR. Some patients with limited cutaneous systemic sclerosis develop isolated pulmonary hypertension with a similar clinical course. Therefore, we have measured the acute hemodynamic response to inhaled NO in such patients.
4612. Fibrin D-dimer and beta-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin.
作者: G Y Lip.;P L Lip.;J Zarifis.;R D Watson.;D Bareford.;G D Lowe.;D G Beevers.
来源: Circulation. 1996年94卷3期425-31页
Previous studies have demonstrated increased markers of thrombogenesis in patients with atrial fibrillation (AF), suggesting the presence of a hypercoagulable or prothrombotic state. The objective of this study was to determine the effects of introducing ultra-low-dose warfarin (1 mg), conventional warfarin, and aspirin. (300 mg) therapy on thrombogenesis and platelet activation in AF.
4613. Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Results of the Diltiazem in Dilated Cardiomyopathy Trial.
作者: H R Figulla.;F Gietzen.;U Zeymer.;M Raiber.;J Hegselmann.;R Soballa.;R Hilgers.
来源: Circulation. 1996年94卷3期346-52页
Evidence is arising that calcium antagonists in idiopathic dilated cardiomyopathy (IDC) may have beneficial effects on virus-induced cardiopathology, alcohol toxicity, micro-circulatory disorders, and impaired calcium cycling, all possibly involved in the pathogenesis of the disease. Thus, the effect of adjunct diltiazem (60 to 90 mg TID) on standard treatment was investigated.
4614. Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Results of a randomized, double-blind, placebo-controlled trial.
作者: G L Schaer.;L J Spaccavento.;K F Browne.;K A Krueger.;D Krichbaum.;J M Phelan.;W O Fletcher.;C L Grines.;S Edwards.;M K Jolly.;R J Gibbons.
来源: Circulation. 1996年94卷3期298-307页
RheothRx (poloxamer 188) is a surfactant with hemorheological and antithrombotic properties that reduces myocardial reperfusion injury in animal models of myocardial infarction. The purpose of the present study was to evaluate the safety and efficacy of adjunctive therapy with poloxamer 188 in patients receiving thrombolytic therapy for acute myocardial infarction.
4615. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study.
作者: B Lamarche.;S Moorjani.;P J Lupien.;B Cantin.;P M Bernard.;G R Dagenais.;J P Després.
来源: Circulation. 1996年94卷3期273-8页
Results obtained largely from case-control studies have suggested that an elevated plasma concentration of apolipoprotein (apo) B may be considered an important risk factor for ischemic heart disease (IHD). Prospective data on the relevance of measuring apo A-I and apo B levels in the assessment of IHD risk, however, remain sparse as well as controversial.
4616. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study.
作者: G B Mancini.;G C Henry.;C Macaya.;B J O'Neill.;A L Pucillo.;R G Carere.;T J Wargovich.;H Mudra.;T F Lüscher.;M I Klibaner.;H E Haber.;A C Uprichard.;C J Pepine.;B Pitt.
来源: Circulation. 1996年94卷3期258-65页
Angiotensin-converting enzyme (ACE) inhibitors may exert some of their benefits in the therapy of hypertension, congestive heart failure, and acute myocardial infarction by their improvement of endothelial dysfunction. TREND (Trial on Reversing ENdothelial Dysfunction) investigated whether quinapril might improve endothelial dysfunction in normotensive patients with coronary artery disease and no heart failure, cardiomyopathy, or major lipid abnormalities so that confounding variables that affect endothelial dysfunction could be minimized.
4617. Transcatheter coil occlusion of surgical fenestration after Fontan operation.
Fenestration of the Fontan circulation that results in a residual right-to-left shunt has improved operative survival rates among high-risk patients. Late closure of the fenestration by use of a transcatheter umbrella device has achieved separation of the systemic and pulmonary venous circulations, "completing" the Fontan pathway. Because use of umbrella devices is restricted, many institutions continue to perform only nonfenestrated Fontan procedures.
4618. Quality of life, employment status, and anginal symptoms after coronary angioplasty or bypass surgery. 3-year follow-up in the Randomized Intervention Treatment of Angina (RITA) Trial.
The Randomized Intervention Treatment of Angina (RITA) trial compares initial policies of percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass graft surgery (CABG) in 1011 patients with angina. This report assesses the impact of these revascularization procedures on angina, quality of life (according to the Nottingham Health Profile), and employment over 3 years of follow-up.
4619. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers.
Chronic smoking is associated with endothelial dysfunction, an early stage of atherosclerosis. It has been suggested that endothelial dysfunction may be a consequence of enhanced degradation of nitric oxide secondary to formation of oxygen-derived free radicals. To test this hypothesis, we investigated the effects of the antioxidant vitamin C on endothelium-dependent responses in chronic smokers.
4620. Modulation of oxidant stress in vivo in chronic cigarette smokers.
Free radical-induced oxidative damage is thought to be involved in the pathogenesis of diseases associated with cigarette smoking. We examined the production of 8-epi-prostaglandin (PG) F2 alpha, a stable product of lipid peroxidation in vivo, and its modulation by aspirin and antioxidant vitamins in chronic cigarette smokers.
|